Skip to content
Open access

Relationship between initial dose, dose intensity, and survival in unresectable pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid

Aug 2026 · Scientific Reports · 0 citations

TL;DR

Reduced starting dose and RDI <80% were not associated with inferior survival, suggesting that individualized dose modification may be feasible, and future prospective studies are warranted to refine NFF dosing strategies.

Abstract

While nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard second-line regimen for unresectable pancreatic cancer (uPC) after gemcitabine-based therapy, the effects of initial dosing and relative dose intensity (RDI) in routine practice are unclear. We retrospectively analyzed 161 patients (median age 67 years; 55% male) with uPC treated with NFF at 20 Japanese institutions (June 2020–May 2021), comparing standard vs. reduced starting dose and RDI ≥80% vs. <80%. Overall survival (OS) was 8.1 vs. 8.8 months for standard vs. reduced dose ( p = 0.47; hazard ratio [HR], 1.15) and 7.5 vs. 9.2 months for RDI ≥80% vs. <80% ( p = 0.39; HR, 0.85). Progression-free survival (PFS) was 3.4 vs. 3.2 months ( p = 0.43) and 2.8 vs. 4.4 months ( p = 0.13), respectively, with similar response and disease control rates. Anemia, thrombocytopenia, and vomiting occurred more frequently in patients administered the standard starting dose, whereas severe non-hematologic adverse events were more frequently observed for RDI <80%. Reduced starting dose and RDI <80% were not associated with inferior survival, suggesting that individualized dose modification may be feasible. Future prospective studies are warranted to refine NFF dosing strategies.

Read PDF

Similar papers

Jul 2026

Early lenvatinib dose intensity is associated with survival in super-older adults (≥80 years) with hepatocellular carcinoma: a real-world comparison with atezolizumab-bevacizumab.

OBJECTIVE To compare lenvatinib (LEN) and atezolizumab plus bevacizumab (Atezo + Bev) as first-line therapy in super-older adults (≥80 years) with hepatocellular carcinoma (HCC) and evaluate whether early relative dose intensity (RDI) is associated with outcomes. METHODS This retrospective cohort study included super...

Masamichi Kimura, K. Nishikawa, Jun Imamura et al. · 0 citations
Open access Sep 2026

Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.

KRAS G12D mutations drive approximately 40% of pancreatic ductal adenocarcinoma (PDAC) cases and foster an immunosuppressive tumor microenvironment. This phase 1/2 trial (NCT06427239) evaluated HRS-4642, a selective KRAS G12D inhibitor, combined with the PD-L1 blockade adebrelimab in 48 pretreated patients with metasta...

S. Shi, Miao-Yan Wei, N. Du et al. · 2 citations
Open access Sep 2026

Correlation of bevacizumab relative dose intensity with first-line treatment outcomes in advanced epithelial ovarian cancer.

OBJECTIVE To evaluate the association between bevacizumab relative dose intensity (RDI) and first-line treatment outcomes in advanced epithelial ovarian cancer. METHODS We retrospectively analyzed 72 patients treated with first-line bevacizumab plus paclitaxel-platinum chemotherapy between January 2019 and September...

Li-Ming Zhang, Mei-Lin Chen, Zhen Yang et al. · 0 citations
Open access Sep 2026

Hepatic arterial infusion chemotherapy plus lenvatinib with or without PD-1 inhibition for unresectable hepatocellular carcinoma: a retrospective cohort study.

The benefit of adding programmed cell death protein 1 (PD-1) blockade to hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib for unresectable hepatocellular carcinoma remains uncertain. This single-center retrospective cohort study included 373 patients. After propensity score matching, 107 patients treated w...

Hai-Dong Yu, Cun-Kai Ma, C. Yangdan et al. · 0 citations
Review Open access Sep 2026

Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study

Extended follow-up confirms that first-line pembrolizumab plus chemotherapy improves efficacy and maintains a manageable safety profile compared with placebo plus chemotherapy, regardless of PD-L1 status, supporting this combination as a first-line treatment option for locally advanced or metastatic HER2-negative gastr...

S. Rha, L. Wyrwicz, P. Yanez et al. · 1 citation · ⚡1

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.